What the FDA labels say about taking them together
Atrasentan and gemfibrozil
Gemfibrozil's FDA label of April 10, 2026 names atrasentan in its drug interactions section; the atrasentan label PlainMeds reads does not name gemfibrozil. The gemfibrozil label: “(D) OATP1B1 substrates: Gemfibrozil is an inhibitor of OATP1B1 transporter and may increase exposure of drugs that are substrates of OATP1B1.”
Check it at the source: the atrasentan FDA label on DailyMed (effective June 12, 2026, Novartis Pharmaceuticals Corporation); the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC).
What does the atrasentan label say about gemfibrozil?
Atrasentan's label (effective June 12, 2026) does not name gemfibrozil in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VANRAFIA), Novartis Pharmaceuticals Corporation, effective June 12, 2026 (SPL set 9a7e7f85-bfd0-44a0-beda-3bcfa8215c64), via openFDA; the full label on DailyMed
What does the gemfibrozil label say about atrasentan?
Gemfibrozil label, drug interactions(D) OATP1B1 substrates: Gemfibrozil is an inhibitor of OATP1B1 transporter and may increase exposure of drugs that are substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan).
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atrasentan | Gemfibrozil | |
|---|---|---|
| Labeled for | n/a | High cholesterol, Heart attack and coronary artery disease |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | $0.104 per tablet 600 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once